anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In 2023, approximately 6.7 million diagnosed cases of Alzheimer's disease and related dementias (ADRD) were reported in the United States, with 83% of the caregiving burden shouldered by unpaid family members or friends. The duration of ADRD varies between 4-20 years, during which individuals often transition into a state of complete dependency. Without family caregivers, the long-term services and support system would be unsustainable. The dearth of accessible support for ADRD caregivers constitutes a significant public health emergency. Caregivers are frequently uncertain of which services are needed, available, and how to gain access - often leaving those most vulnerable without essential support. When queried about service underuse, study respondents who participated in the K99 phase of this project highlighted an information deficit tailored to specific cultures, demographics, and dementia types. They described the excess of online information as overwhelming, often irrelevant, impractical, or unaffordable. Existing technology-based solutions targeted toward enhancing personalized caregiver support are limited. Leveraging continued innovations in technology to inform the training and testing of machine learning algorithms, which can match and update resources while accounting for individual needs, preferences (in-person, virtual), and barriers (e.g., employment, lack of respite care), holds great potential to enhance the precision of service linkage for ADRD caregivers. This R00 project aims to develop, refine, and pilot test CarePair (formerly the Caregiver Resource Room), a web-based assessment and service referral platform for dementia caregivers. CarePair will leverage innovative machine learning algorithms to holistically evaluate caregivers' evolving needs, their barriers, and preferences to generate personalized service referrals relevant to their areas of identified need. Thus, the specific aims of the R00 are to 1) Use mixed-method and focus group data from the K99 phase to inform the iterative development of the CarePair, which includes a digital self-assessment tool employing machine learning to identify needs, categorize them, and generate targeted service recommendations; 2) Evaluate front- and back-end usability (e.g., via task analysis, heuristic evaluation) of the tool's content, design, features, functionality, and accuracy of service output. Feedback will inform modifications and iterative refinement of the CarePair Version 2.0; 3) Conduct a pilot randomized controlled trial to assess the feasibility, acceptability, and preliminary efficacy of CarePair in enhancing service awareness, addressing unmet needs, and improving mental health. The proposed research aligns with the NIA's strategic initiative to foster research scientists in aging and to develop promising interventions to better engage and support the well-being of ADRD family caregivers.
PURPOSE:To obtain an external remedy for skin diseases directly applicable to affected sites, having excellent action with a small amount free from skin irritation and systemic side effects, containing a salt of ketotifen, a fat-soluble basic substance and a glycol. CONSTITUTION:A salt of ketotifen (e.g. ketotifen fumarate) is dissolved in a glycol (e.g. propylene glycol), a fat-soluble basic substance (e.g. alkylamine) is added to the prepared amine, which is optionally mixed with another additive and stirred to give the aimed substance. This external remedy for skin diseases contains 0.01-5wt.% salt of ketotifen, 0.008-15wt.% fat-soluble basic substance and 3-90wt.% glycol. The remedy is preferably prepared into a dosage form such as ointment or solution. The remedy is effective for humid tetter, dermatitis, urticaria, atopic dermatitis and insect bite and further has inhibitory action on liberation of chemical mediator of ketotifen and anti-histamine action.
For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded. Follow-up was performed to determine whether the patients had a re-admission within 3 months.
### Initiating Treatment with LORTAB ELIXIR 

The usual adult dosage is 11.25 milliliters every 4 to 6 hours as needed for pain. The total daily dosage for adults should not exceed 67.5 milliliters. 

The usual dosages for children are given by the table below and is to be given every 4 to 6 hours as needed for pain. The total daily dosage for children should not exceed 6 doses per day. These dosages correspond to an average individual dose of 0.20 mL/kg of LORTAB ELIXIR (providing 0.135 mg/kg of hydrocodone bitartrate and 4.0 mg/kg of acetaminophen). Dosing should be based on weight whenever possible. 

It is of utmost importance that the dose of LORTAB ELIXIR be administered accurately. A household teaspoon or tablespoon is not an adequate measuring device, especially when one-half or three-fourths of a teaspoonful is to be measured. Given the variability of the household spoon measure it is strongly recommended that caregivers obtain and use a calibrated measuring device. Health care providers should recommend a dropper that can measure and deliver the prescribed dose accurately, and instruct caregivers to use extreme caution in measuring the dosage. 

### Conversion from Other Opioids to LORTAB ELIXIR 

There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of LORTAB ELIXIR. It is safer to underestimate a patient's 24-hour LORTAB ELIXIR dosage than to overestimate the 24-hour LORTAB ELIXIR dosage and manage an adverse reaction due to overdose. 

### Conversion from LORTAB ELIXIR to Extended-Release Hydrocodone 

The relative bioavailability of hydrocodone from LORTAB ELIXIR compared to extended-release hydrocodone is unknown, so conversion to extended-release tablets must be accompanied by close observation for signs of excessive sedation and respiratory depression.
AIM: To investigate the incidence rate of urinary tract infections (UTIs) among febrile infants aged ≤60 days before, during, and after the COVID-19 pandemic.
METHODS: We conducted a retrospective study in 2 Swedish paediatric emergency departments between 2014 and 2022. We included full-term infants aged ≤60 days with fever without source. We calculated the annual incidence rate of UTI per 1000 births.
RESULTS: We included 1589 full-term infants with fever without source. In 2020, 89 infants were evaluated in the emergency department versus 203-259 in 2017-2019. In 2020, the incidence rate of UTI was 1.43 per 1000 births/year versus 2.18-2.37 in 2017-2019. The median age, sex, fever duration, and urine testing were similar between the years 2017 and 2020.
CONCLUSION: The number of febrile infants who presented to the paediatric emergency department and the incidence rate of UTIs decreased in 2020. This decrease might imply a systematic misdiagnosis of UTIs in infants with febrile viral infections. A more selective urine testing approach for febrile, previously healthy, infants should be considered to mitigate UTI misdiagnosis and its potential harmful effects.
Generally, the Kou Sha therapy group needs to kou sha 2-3 times, and after each kou sha, it is necessary to rest for 1 week or all the shas in the part fade before they can be kou sha again. The duration of treatment is 1 menstrual cycle.
Primary congenital glaucoma is a rare disease that occurs in early birth and can lead to low vision. Evaluating affected children is challenging and there is a lack of studies regarding color vision in pediatric glaucoma patients. This cross-sectional study included 21 eyes of 13 children with primary congenital glaucoma who were assessed using the Farnsworth D-15 test to evaluate color vision discrimination and by spectral domain optical coherence tomography to measure retinal fiber layer thickness. Age, visual acuity, cup-to-disc ratio and spherical equivalent data were also collected. Global and sectional circumpapillary and macular retinal fiber layer thicknesses were measured and compared based on color vision test performance. Four eyes (19%) failed the color vision test with diffuse dyschromatopsia patterns. Only age showed statistical significance in color vision test performance. Global and sectional circumpapillary and macular retinal fiber layer thicknesses were similar between the color test outcomes dyschromatopsia and normal. While the color vision test could play a role in assessing children with primary congenital glaucoma, further studies are needed to correlate it with damage to retinal fiber layer thickness.
The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
The invention relates to a moisture-preserving and hair-brightening hair oil. According to hair caring modes of ancient people and through improving the formula and the process flow, the moisture-preserving and hair-brightening hair oil, having effects of moisture preserving, hair brightening and repairing, is prepared and is an optimum moisture-preserving and hair-brightening hair oil for nursing and maintaining hair. In addition, phenomena of dry, split and broken hair due to bleaching, dyeing and perming can be improved. The hair oil is scalp harmless and does not cause dandruff. The hair oil is suitable for any hair types. 1. According to technical requirements, rapeseed oil, plant oil, mineral oil, sesame oil, white oil, vaseline and essential oil are mixed by ratio; 2. a small amount of the hair oil can be applied to the wet hair after washing to make the hair brighter and moisture-retentive and the hair oil has relatively good hair caring effects and is suitable for any hair types; 3. raw materials all can be bought on the market or in chemical raw material stores, the average price of the raw materials being eighteen yuan per kilogram.
PURPOSE: The study intends to clarify the optimal endoscopic endonasal surgical strategy for symptomatic Rathke's cleft cysts (RCCs).
METHODS: We retrospectively analyzed patients with RCCs that underwent EEA surgery. The strategy for surgical and reconstruction method selection was presented. Patients were split into groups of fenestration open or closed. Pre- and postoperative symptoms, imaging, ophthalmologic, and endocrinologic exams were reviewed. The incidence of complications and the recurrence rates were determined.
RESULTS: The 75 individuals were all received primary operations. The fenestration closed group contained 32 cases, while the fenestration open group contained 43 cases. The median follow-up period was 39 months. The three primary complaints were headache (n = 51, 68.00%), vision impairment (n = 45, 60.00%), and pituitary dysfunction (n = 16, 21.33%). Of the 51 patients with preoperative headaches, 48 (94.12%) reported improvement in their symptoms following surgery. Twenty-three out of 45 patients (51.11%) experienced an improvement in visual impairment. Pituitary dysfunction was found improved in 14 out of 16 individuals (87.50%). There was no discernible difference in the rate of symptom alleviation between both groups. There were three patients (3/75, 4.00%) had cyst reaccumulation. One of them (1/75, 1.33%), which needed reoperation, was healed using pterional approach. In term of complications, cerebral infections occurred in two patients (2/75, 2.67%). Both of them recovered after antibiotic treatment. No postoperative cerebrospinal fluid rhinorrhea occurred. One patient (1/75, 1.33%) in the open group experienced epistaxis. There was no persistent hypopituitarism or diabetes insipidus (DI). Analysis of headache related factors showed that the presence of wax like nodules was related to it.
CONCLUSION: RCC was successfully treated with endoscopic endonasal surgery with few problems when the fenestration was kept as open as feasible. Preoperative identification of T2WI hypointense nodules may be a potential reference factor for surgical indication.
SEPTOCAINE contains epinephrine, a vasoconstrictor that can cause local or systemic toxicity and should be used cautiously. Local toxicity may include ischemic injury or necrosis, which may be related to vascular spasm. SEPTOCAINE should be used with caution in patients during and following the administration of potent general anesthetic agents, since cardiac arrhythmias may occur under such conditions. Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.

The American Heart Association has made the following recommendation regarding the use of local anesthetics with vasoconstrictors in patients with ischemic heart disease: "Vasoconstrictor agents should be used in local anesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the analgesia rendered more profound. When a vasoconstrictor is indicated, extreme care should be taken to avoid intravascular injection. The minimum possible amount of vasoconstrictor should be used." (Kaplan, 1986).

It is essential to aspirate before any injection to avoid administration of the drug into the blood stream.
Participants will recieve pirtobrutinib as bridging therapy from day -27 to day -7. Participants randomized to Arm A (n=30) will continue to receive concurrent pirtobrutinib ("con-pirto"), starting at day -6 and continued until 1-year post-CD19 CAR T-cell therapy with brexucel.
The invention provides external use traditional Chinese medicine for curing cerebral arteriosclerosis. The external use traditional Chinese medicine for curing cerebral arteriosclerosis is formed by a basic remedy and an adjuvant. The basic remedy is formed by 43 crude drugs such as Ligusticum wallichii, Angelica sinensis, radix paeoniae alba and radix rehmanniae recen. The adjuvant is formed by safflower carthamus, liquorice, centipede and Shanxi mature vinegar. The external use traditional Chinese medicine can obviously improve the condition of cerebral ischemia hypoxia, an obvious protection effect on focal cerebral ischemia is achieved, the neurobehavioral abnormalities caused by ischemia is improved, red blood cell de-formability can be obviously improved, so that the blood viscosity is improved, ischemic vascular diseases can be better improved and recovered, thrombosis is reduced, microcirculation perfusion and organ and tissue oxygen and nutrient supply are improved, and an obvious therapeutic effect on cerebral vascular sclerosis diseases is achieved. Meanwhile, the external use traditional Chinese medicine for curing cerebral arteriosclerosis further has the advantages of being safe, effective, fast, easy to operate, free of pains and economical.
Quantitative trait locus analysis identified independent novel loci in cucumbers responsible for resistance to races 0 and 1 of the anthracnose fungal pathogen Colletotrichum orbiculare. Cucumbers have been reported to be vulnerable to Colletotrichum orbiculare, causing anthracnose disease with significant yield loss under favorable conditions. The deployment of a single recessive Cssgr gene in cucumber breeding for anthracnose resistance was effective until a recent report on high-virulent strains infecting cucumbers in Japan conquering the resistance. QTL mapping was conducted to identify the resistance loci in the cucumber accession Ban Kyuri (G100) against C. orbiculare strains 104-T and CcM-1 of pathogenic races 0 and 1, respectively. A single dominant locus An5 was detected in the disease resistance hotspot on chromosome 5 for resistance to 104-T. Resistance to CcM-1 was governed by three loci with additive effects located on chromosomes 2 (An2) and 1 (An1.1 and An1.2). Molecular markers were developed based on variant calling between the corresponding QTL regions in the de novo assembly of the G100 genome and the publicly available cucumber genomes. Multiple backcrossed populations were deployed to fine-map An5 locus and narrow the region to approximately 222 kbp. Accumulation of An2 and An1.1 alleles displayed an adequate resistance to CcM-1 strain. This study provides functional molecular markers for pyramiding resistance loci that confer sufficient resistance against anthracnose in cucumbers.
BACKGROUND: Axial symptoms (AS) represent one of the primary complications after cervical spondylotic myelopathy (CSM) surgery. Traditional Chinese Medicine (TCM), as a complementary and alternative therapy, is widely used in the treatment of postoperative AS in CSM. However, it lacks standardised treatment protocols, uniform therapeutic criteria, assessment methods and a sufficiently in-depth understanding of its mechanisms of action. These shortcomings impact the credibility of TCM treatment in clinical practice.
METHODS AND ANALYSIS: We will conduct comprehensive searches, both manual and electronic, on literature published up to 31 July 2024, and database searches will commence after the publication of this agreement, with an estimated commencement date of 1 October 2024 and the end date of 31 March 2025, without language restrictions. Key databases such as MEDLINE, PubMed, Embase, Web of Science, Cochrane Library, WHO International Clinical Trial Registration Platform, China National Knowledge Network, China Biomedical Literature Database, China Scientific Journal Database and Wanfang Database will be explored. In addition, we will include resources such as library journals and conference abstracts. After identifying and screening all randomised controlled trials focused on TCM for postoperative AS of CSM, the two investigators will conduct a meta-analysis of the included studies. The results will be summarised as the risk ratio for binary data and the standardised or weighted average difference for continuous data.
ETHICS AND DISSEMINATION: Ethical approval is not required since this review does not involve individual patient data. The review's findings will provide clinicians with evidence on using TCM treatment for AS post-CSM surgery, disseminated through peer-reviewed publications or conferences.
PROSPERO REGISTRATION NUMBER: CRD42024505160.
PURPOSE: A cosmetic composition containing natural materials for scalp is provided to prevent and treat scalp itch, suppress dandruff and ensure cell proliferation. CONSTITUTION: A cosmetic composition for scalp contains Solanum melongena L. root, Chrysanthemum zawadskii var. latilobum, Ipomoea batatas Lam., Zizyphus jujuba Miller var. Inermis Rehd, Laminaria Japonica Areschoug and Pinellia ternata Breit. The mixture extract is isolated using C1-C4 alcohol, or its hydrous alcohol. The alcohol is methanol or ethanol. The hydrous alcohol is 30% of hydrous ethanol, or 70% of hydrous ethanol. The mixture is contained in 0.001~5 weight% based on total dry weight of the composition. The cosmetic composition for scalp is used in the form of shampoo, rinse, pack or tonic.
Lymphomas originating from the meninges without brain or systemic involvement represent an extremely rare type of primary central nervous system lymphomas. Here, we report a case of primary dural lymphoma in a 3-year-old boy who was brought to the hospital due to headache, nausea, and vomiting episodes ongoing for several days. An acute hematoma in the right frontoparietal region was detected on a brain CT scan. The patient underwent surgery to remove the hematoma, which was then sent for pathologic examination. The pathology report revealed lymphoblastic B-cell lymphoma with a Ki-67 proliferation index of 80%. Radiologic and FDG-PET/CT imaging, as well as bone marrow examination, did not reveal any systemic disease. The NHL BFM 2012 lymphoblastic lymphoma treatment protocol was started and successfully completed. The patient has been followed for ~2 years and is still alive and disease-free. This is the first case of pediatric primary dural lymphoblastic B-cell lymphoma ever reported in the literature.
Based on findings from animals and its mechanism of action, ELLENCE can cause fetal harm when administered to a pregnant woman; avoid the use of ELLENCE during the 1st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of epirubicin during the 2nd and 3rd trimesters. In animal reproduction studies, epirubicin was embryo-fetal lethal and caused structural abnormalities in rats and rabbits at doses less than the maximum recommended human dose on a body surface area basis. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of ELLENCE. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of ELLENCE. Advise male patients with pregnant partners to use condoms during treatment and for at least 7 days after the last dose of ELLENCE [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1), and Nonclinical Toxicology (13.1)].
A health management and counseling system combined with genetic testing comprises an interactive device, a database, and a computing center. The interactive device includes an input interface and a display interface. The database stores multiple potential disease characteristics, multiple potential disease categories, and multiple counseling recommendation information. The computing center is provided with genetic testing data, a daily physiological data, and a medical record data. According to the genetic testing data, the daily physiological data, and the medical record data, the computing center are compared to determine whether each of the potential disease characteristics corresponded to at least one potential disease category and whether at least one counseling recommendation information matched these potential disease characteristics. These potential disease categories and counseling recommendation information are then transmitted to the display interface.